Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

The Avalanche Approach

Currently, wet age-related macular degeneration is treated with frequent injections of anti-VEGF protein directly into the eyeball. This creates a burden for both patients and physicians, and limits access for those who are not able to comply with frequent visits and injections.

Learn More About The Avalanche Approach:

Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

June 15, 2015

MENLO PARK, Calif., June 15, 2015 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL) today announced that its Phase 2a clinical study for AVA-101 met its 12-month primary endpoint, based on ophthalmic and systemic safety, demonstrating that AVA-101 was well tolerated with a favorable safety profile in subjects with wet age-related macular degeneration (wet AMD).

Read More

Read All Avalanche News